$SRNE HERE ARE SORRENTO PIPELINE HIGHLIGHTS WITH RUMORED ACEA AQUSITION...a lot of news coming. COVID-19 Programs---------------- COVI-TRACE™ Diagnostic Test 45 min. COVI-TRACK™ Antibody Test 8 min. COVI-STIX 15 min. COVI-GUARD™ Neutralizing Antibody COVI-AMG™ Neutralizing Antibody 2020 plasmid DNA 2020 COVI-DROPS nasal 2020 aMSC cell therapy phase 1 ABIVERTINIB Cytokine Storm phase 2 Celularity phase 1/2 (25% interest) CANCER Immunotherapy------------- CD38 CAR-T Multiple Myeloma CD38 DAR-T Multiple Myeloma CD38 ADC Amyloidosis Seprehvir™ Solid Tumors ABIVERTINIB NSCLC phase 3 ABIVIRTINIB lymphomas phase 2 ADNIC Solid and Liquid Tumors phase 2 NON-OPIOID Pain-------------- RTX (resiniferatoxin)Epidural route Terminal Cancer Pain Orphan status RTX (resiniferatoxin) Intra-articular route Moderate to Severe OA RTX (resiniferatoxin)TKR deferment SP-102 lumbar/sciatic pain pivotal phase 3 results 2021 ACEA Therapeutics portfolio Oncology-------------- Abivertinib EGFR T790M+(2nd Line)phase 3 NDA approval China EGFR mut+(1st Line) Lymphomas China phase 2 AC0002 CNS Tumors Global AC0078 Pan-TRK inhibitor Global ACT01 Multiple oncology indications Global ACT02 Multiple oncology indications Global ACT03 Multiple oncology indications Global ACT04 Multiple oncology indications Global Autoimmune Disease------------ AC0058 phase 2